Core Viewpoint - Cue Biopharma, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $20 million to support its clinical-stage biopharmaceutical development efforts [1][2]. Group 1: Offering Details - The public offering includes 13,530,780 shares of common stock and warrants for an aggregate of 3,382,695 shares, as well as pre-funded warrants for 11,469,216 shares and accompanying warrants for 2,867,304 shares [1]. - The combined public offering price for each share of common stock and accompanying warrant is set at $0.79, while the pre-funded warrant and accompanying warrant are priced at $0.789 [1]. - The offering is expected to close around April 16, 2025, pending customary closing conditions [1]. Group 2: Management and Company Background - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of therapeutic biologics to engage and modulate disease-specific T cells for cancer and autoimmune diseases [5]. - The company utilizes its proprietary platform, Immuno-STAT™, designed to harness the immune system's potential without broad systemic immune modulation [5]. - The management team possesses extensive expertise in immunology, protein engineering, and the clinical development of protein biologics [6].
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering